Delving into the Latest Updates on Biodol Therapeutics SAS with Synapse

Overview

Basic Info

Introduction

Established in 2015, Biodol Therapeutics is dedicated to creating pioneering compounds for managing chronic pain (CP). The company has pinpointed the Receptor Tyrosine Kinase (RTK) FLT3 as a critical factor in triggering and sustaining chronic neuropathic pain (NP) conditions. Biodol Therapeutics' proprietary approach involves developing extracellular inhibitors of the FLT3 receptor.

Author: Thouaye, Maxime ; Giraudin, Aurore ; Valmier, Jean ; Dallel, Radhouane ; Tassou, Adrien ; Mechaly, Ilana ; Rivat, Cyril ; Carroll, Patrick ; Rognan, Didier ; Sonrier, Corinne ; Leyris, Jean-Philippe ; Ruel, Jerome ; Bertin, Juliette ; Diouloufet, Lucie ; Alves, Stacy ; Sokoloff, Pierre ; Venteo, Stephanie ; Sar, Chamroeum ; Jouvenel, Antoine ; Delmas, Patrick ; Mallie, Sylvie ; Antri, Myriam ; Daubeuf, Francois ; Frossard, Nelly

AbstractNavigating the duality of opioids' potent analgesia and side effects, including tolerance and hyperalgesia, is a significant challenge in chronic pain management, often prompting hazardous dose escalation to maintain analgesic effects. The peripheral mu-opioid receptor (MOR) is known to mediate these contradictory effects. Here, we show that the fms-like tyrosine kinase receptor 3 (FLT3) in peripheral somatosensory neurons drives morphine tolerance and hyperalgesia. We found that chronic morphine treatment increases FLT3 and MOR co-expression, and that inhibiting FLT3 represses MOR-induced hyperactivation of the cyclic adenosine monophosphate (cAMP) signaling pathway, mitigating maladaptive excitatory processes engaged after chronic morphine treatment. Furthermore, in postsurgical or inflammatory models of chronic pain, co-administering morphine with a FLT3-specific inhibitor not only prevents or suppresses tolerance and hyperalgesia but also potentiates the analgesic efficacy of morphine. Our findings suggest that pairing morphine with FLT3 inhibitors could become a promising avenue for chronic pain management to safely harness the power of opioids, without the risk of dose escalation. By enhancing morphine analgesic potency through FLT3 inhibition, this approach could minimize opioid dosage, thereby curtailing the risk of addiction and other opioid-related side effects.

100 Deals associated with Biodol Therapeutics SAS

Login to view more data

100 Translational Medicine associated with Biodol Therapeutics SAS

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data